Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects With Confirmed Influenza Infection
Conditions
Interventions
zanamivir aqueous solution
Locations
110
United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Stamford, Connecticut, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
Start Date
November 1, 2009
Primary Completion Date
February 1, 2015
Completion Date
February 1, 2015
Last Updated
March 28, 2017
NCT06355232
NCT06622590
NCT05227001
NCT05446740
NCT06602531
NCT05823974
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions